|Day Low/High||93.11 / 93.66|
|52 Wk Low/High||72.30 / 92.39|
For my portfolio, you can't beat this SBUX competitor -- and for a cup of coffee.
Ultragenyx scored its second FDA drug approval in six months. The orphan disease specialist also picked up its second Rare Pediatric Disease Priority Review Voucher; its first sold for $130 million.
Jim Cramer and our other experts discuss the FAANG stocks, a market bottom, and potential biotech targets.
Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.
Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.
Jim Cramer says we're seeing powerful reminders that there's a better time to sell than in the teeth of a decline. Investors must use discipline to their advantage.
Here's what you need to know for Monday, April 9.
Stocks rise Monday following tweets from Donald Trump that appeared to indicate the U.S. was softening its approach in its trade battle with China.
Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.
A look at possible second-quarter M&A activity in the biotech sector.
Two failed bounces this year have made it tougher for stocks to build strong sustained momentum.
Markets around the globe last week were tumultuous after both China and the U.S. proposed tariffs on imported goods as investors weigh whether the countries will come to the table to negotiate an end to the spat.
U.S. stock futures rise Monday following indications that Donald Trump was softening his approach toward China; Deutsche Bank ousts CEO John Cryan; Novartis buys AveXis; Facebook to notify users whose data may have been shared with Cambridge Analytica.
The acquisition is a big move for Novartis CEO Vas Narasimhan, who took the helm in February.
Jim Cramer takes a closer look at Blackberry, SkyWest, Apache, Philip Morris International, PetMed Express, Iron Mountain, Novartis.
This market is deceptive and you need to recognize your sense of timing is not infallible. So, adjust your scales and get ready for next week, says Jim Cramer.
The biopharmaceutical company, which won controversial FDA approval for a Duchenne Muscular Dystrophy drug, now confronts patient groups asking HHS to take its patents and drop the price of that drug.
As President Trump tees up a set of 25% tariffs on a wide range of products against China trade, generic drug makers as well as their patients likely will be affected.
M&A activity kicks into high gear going into the final days of the first quarter. If the broader stock market doesn't pop on this news, it would be a red flag.
Cooling tensions with China aren't enough to save investors on Tuesday.
With Wall Street responding to one of the strongest rallies in years, here's what you need to know premarket Tuesday.
U.S. stock futures rise and global stocks extend their rally; Novartis to sell 36.5% stake in joint venture to partner GSK for $13 billion; Facebook's Mark Zuckerberg won't face U.K. lawmakers.
Wall Street's best day in nearly three years has global stocks on the move Tuesday, with U.S.-China trade talks and a wave of late quarter M&A boosting markets around the world.
Novartis subsidiary Sandoz Canada will work with cannabis producer Tilray to produce non-smokable medical cannabis products in Canada, becoming the first Big Pharma company to get into medical pot.
Here's what you need to know now for Tuesday, March 6.
Morgan Stanley analyst David Risinger is upbeat about the drugmaker's generic drug growth prospects in the U.S.
The Swiss pharmaceutical firm's U.S. generic pill business could attract as much as $1.6 billion, Reuters reported.
This is the second generic Copaxone 40 mg/mL greenlighted by the U.S. Food and Drug Administration.
Stocks ended higher on Tuesday.
Chief executive David Hung resigned from the Basel, Switzerland, biotech after just 10 months on the job.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.